Publications from the Fuhrmann Lab

Gregor Fuhrmann on ORCID 0000-0002-6688-5126 and on Google Scholar

30. Schulz E, Karagiannis A & Fuhrmann G* (2020) Hot EVs – how temperature affects extracellular vesicles. European Journal of Pharmacy and Biopharmacy, 146:55

29. Woith E, Fuhrmann G* & Melzig MF* (2019) Extracellular Vesicles – Connecting Kingdoms. International Journal of Molecular Sciences, 20:5965

28. Hoppstädter J, Dembek A, Barghash A, Fecher-Trost C, Fuhrmann G, Koch M, Kraegeloh A, Huwer H, Kiemer AK (2019) Toll-like receptor 2 release by macrophages: an anti-inflammatory program induced by glucocorticoids and lipopolysaccharide. Frontiers in Immunology doi.org/10.3389/fimmu.2019.01634

27.     Richter M, Fuhrmann K & Fuhrmann G* (2019) Evaluation of the storage stability of extracellular vesicles. Journal of Visualized Experiments, 147:e59584

See the full video protocol here.

26.    Thery C, Witwer K […] Fuhrmann G et al. (2019) Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV): an update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 8:1535750

25.    Schulz E, Goes A, Panter F, Koch M, Garcia R, Müller R, Fuhrmann K & Fuhrmann G* (2018) Biocompatible bacteria-derived vesicles show inherent antimicrobial activity. Journal of Controlled Release 290:46

24.     Fuhrmann G* (2018) Luminal coating of the intestine. Nature Materials  17:754

23.    Frank J, Richter M, De Rossi C, Lehr CM, Fuhrmann K & Fuhrmann G* (2018) Extracellular vesicles protect glucuronidase model enzyme during freeze-drying. Scientific Reports  8:12377

22.    Goes A & Fuhrmann G* (2018) Biogenic and biomimetic carriers as versatile transporters to treat bacterial infections. ACS Infect Diseases  4:881

21.     Fuhrmann G* (2018) Experimental therapies for coeliac diseases. Pharmakon  6(2):44

20.     Fuhrmann G, Chandrawati R et al. (2018) Engineering extracellular vesicles with the tools of enzyme prodrug therapy Advanced Materials  30:1706616

This work was featured as back cover in Advanced Materials

19.     Fuhrmann K & Fuhrmann G* (2017) Recent advances in oral delivery of macromolecular drugs and benefits of polymer conjugation Current Opinion in Colloid & Interface Science  31:67 (*GF corresponding author)

18.     Frank J & Fuhrmann G* (2017) Best before - lyophilisation as novel storage alternative for extracellular vesicles Journal of Extracellular Vesicles  6:sup1, DOI: 10.1080/20013078.2017.1310414 (*GF corresponding author)

17.   Fuhrmann G*, Neuer AL & Herrmann IK (2017) Extracellular vesicles – a promising avenue for the detection and treatment of infectious diseases? European Journal of Pharmaceutics and Biopharmaceutics 118:56 (*GF sole corresponding author)

16.   Fuhrmann G* & Stevens MM (2016) Stability of extracellular vesicles during lyophilisation – implications for their pharmaceutical use. Journal of Extracellular Vesicles 5: 30924-30940 (*GF co-corresponding author)

15.   Whittaker T, Fuhrmann G & Stevens MM (2016) Purifying extracellular vesicles by size exclusion: give it a little longer. Journal of Extracellular Vesicles 5: 30924-30940

14.   Liu M, Fuhrmann G, Johansen P, Leroux J & Gauthier MA (2016) "Bio-hybrid" therapeutics. Frontiers in Bioengineering and Biotechnology doi: 10.3389/conf.FBIOE.2016.01.00919

13.   Santos L, Fuhrmann G, Juenet M, Amdursky N, Horejs C-M, Campagnolo P & Stevens MM (2015) Extracellular stiffness modulates the expression of functional proteins and growth factors in endothelial cells. Advanced Healthcare Materials 4: 2056-2063

12.   Fuhrmann G¹, Herrmann IK¹ & Stevens MM (2015) Cell-derived vesicles for drug therapy and diagnostics: opportunities and challenges. Nano Today 10: 397-409 (¹GF and IH with equal contribution)

11.  Fuhrmann G*, Serio A, Mazo M, Nair R & Stevens MM (2015), Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins. Journal of Controlled Release 205: 35-44 (*GF co-corresponding author)

10.   Fuhrmann G & Leroux J-C (2014) Improving the stability and activity of oral therapeutic enzymes - recent advances and perspectives. Pharmaceutical Research  31:1099-1105

9.    Fuhrmann G, Gauthier MA & Leroux J-C (2013) Polymer-enzyme conjugates for oral drug delivery applications. Chimia  67:685-686

8.   Fuhrmann G, Grotzky A, Lukic R, Matoori S, Luciani P, Zhang B, Yu H, Walde P, Schlüter AD, Gauthier MA & Leroux J-C (2013) Sustained gastrointestinal activity of dendronized polymer-enzyme conjugates. Nature Chemistry 5: 582–589.

This work was highlighted in Nature Chemistry News and Views (2013, 5:557–558)

7.   Matoori S, Fuhrmann G & Leroux J-C (2012) Celiac disease: a challenging disease for pharmaceutical scientists. Pharmaceutical Research 30:619-626

6.   Pinier M, Fuhrmann G, Galipeau H, Rivard H, Murray JA, David CS, Tuckova L, Drasarova H, Leroux J-C & Verdu EF (2012) The copolymer P(HEMA-co-SS) binds gluten and reduces immune response in gluten-sensitized mice and human tissues. Gastroenterology 142: 316-325.e12.

5.   Matoori S, Fuhrmann G, Jessica D Schulz & Leroux J-C (2012) Gluten binden und spalten - neue adjuvante Therapiemöglichkeiten für Zöliakie. Swiss Medical Forum 12:716–717

4.   Fuhrmann G & Leroux J-C (2011) In vivo fluorescence imaging of exogenous enzyme activity in the gastrointestinal tract. Proceedings of the National Academy of Sciences USA 108:9032-9037.

This work was highlighted in numerous daily newspapers in Germany, Switzerland and Austria, in coeliac disease fora, and in ETH Life (August 2011).

3.    Fuhrmann G & Leroux J-C (2010) In vitro evaluation of the stability of proline-specific endopeptidases under simulated gastrointestinal conditions. Journal of Controlled Release 148:e37-e39.

2.    Pinier M¹, Fuhrmann G¹, Verdu E, & Leroux J-C (2010) Prevention measures and exploratory pharmacological treatments of celiac disease. American Journal of Gastroenterology 105:2551-2561 (¹MP and GF with equal contribution)

1.     Bastiat G, Plourde F, Motulsky A, Furtos A, Dumont Y, Quirion R, Fuhrmann G & Leroux  J-C (2010) Tyrosine-based rivastigmine-loaded organogels in the treatment of Alzheimer's disease. Biomaterials 31:6031-6038